Trials / Terminated
TerminatedNCT05813288
A Study to Assess the Effect of Dexpramipexole in Adolescents and Adults With Severe Eosinophilic Asthma (EXHALE-3)
A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Assess the Efficacy, Safety, and Tolerability of Dexpramipexole Administered Orally for 52 Weeks in Participants With Severe Eosinophilic Asthma
- Status
- Terminated
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 654 (actual)
- Sponsor
- Areteia Therapeutics · Industry
- Sex
- All
- Age
- 12 Years – 99 Years
- Healthy volunteers
- Not accepted
Summary
The objective of this clinical study is to investigate the safety, tolerability, and efficacy of dexpramipexole in participants with inadequately controlled severe eosinophilic asthma.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Dexpramipexole Dihydrochloride | Oral administration of dexpramipexole tablet |
| DRUG | Placebo | Oral administration of placebo tablet |
Timeline
- Start date
- 2023-03-27
- Primary completion
- 2025-12-08
- Completion
- 2025-12-08
- First posted
- 2023-04-14
- Last updated
- 2025-12-15
Locations
282 sites across 26 countries: United States, Argentina, Austria, Brazil, Chile, China, Croatia, Czechia, France, Germany, Hungary, India, Israel, Italy, Japan, Lithuania, Mexico, Peru, Puerto Rico, South Africa, South Korea, Spain, Taiwan, Turkey (Türkiye), Ukraine, United Kingdom
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05813288. Inclusion in this directory is not an endorsement.